LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

28.35 2.2

Buy Sell

Overview

Share price change

24h

Current

Min

27.89

Max

28.83

Key metrics
By Trading Economics
Income	-28M 22M
Sales	4.3M 244M
P/E Sector Avg	10.28 57.833
EPS	1.08
Profit margin	9.224
Employees	293
EBITDA	-22M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+48.06% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	64M 1.6B
Previous open	26.15
Previous close	28.35

News Sentiment

By Acuity

75%

25%

324 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 mar 2026, 22:42 UTC

Earnings

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Earnings

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Earnings

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Earnings

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Earnings

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Earnings

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Earnings

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Earnings

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Market Talk

Major News Events

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

48.06% upside

12 Months Forecast

Average 41.25 USD 48.06%

High 62 USD

Low 25 USD

Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

324 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.